A major international cannabis product provider has debuted a new line in Europe’s largest medical cannabis market.
Curaleaf International today announced the launch of THC-rich cannabis oil products through its wholly-owned subsidiary Adven GmbH.
According to the company, the goal is to meet immediate patient needs throughout the next year, incorporating various strengths of THC and CBD formulations in cannabis flowers and oils.
Current projections place the German medical cannabis market value at US$2.1 billion by 2025.
“We are very pleased to bring our first medical cannabis products to market in Germany and, with the rapid extension of our product range in 2021, establishing ourselves as a leader in Europe’s largest medical cannabis market,” says Curaleaf International CEO Antonio Costanzo. “Curaleaf International’s European supply chain, from cultivation to product research and development and EU-GMP manufacturing processes across Europe, means we are able to guarantee a consistency of product and price to clinicians and patients in need of the highest quality medical cannabis.”
Adven Managing Director Julian Vaterrodt says there is an increasing demand from German patients and practitioners for quality, consistent, and reliable European natural alternatives to treat a wide range of conditions.
“Adven is committed to providing a differentiated product and service for the German market,” says Vaterrodt. “We focus on providing a consistent supply of high-quality European medical cannabis and cutting-edge digital technologies to improve the patient and healthcare professional experience.”
Curaleaf is Europe’s largest vertically-integrated cannabis company, working to bring the life-enhancing potential of cannabis to people in need.